A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

NCT02975700 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: PLX3397

Sponsor

Daiichi Sankyo Co., Ltd.

Collaborators

[object Object]